Literature DB >> 21602036

A population-based study of prostate cancer chemotherapy.

V Harris1, K Lloyd, S Forsey, P Rogers, M Roche, C Parker.   

Abstract

The use of chemotherapy in the treatment of prostate cancer is a relatively recent development, with no published data on the patterns of care in the UK. We carried out a population-based study to assess variation in the use of prostate cancer chemotherapy over time in a UK cancer network. Copyright Â
© 2011 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21602036     DOI： 10.1016/j.clon.2011.04.014

Source DB:  PubMed          Journal:  Clin Oncol (R Coll Radiol)        ISSN： 0936-6555            Impact factor:   4.126


  13 in total

1.  Treatment patterns and trends in patients dying of prostate cancer in Quebec: a population-based study.

Authors:  A Dragomir; J Rocha; M Vanhuyse; F L Cury; W Kassouf; J Hu; A G Aprikian
Journal:  Curr Oncol       Date:  2017-08-31       Impact factor: 3.677

2.  Emerging Therapeutic for the Treatment of Skeletal-related Events Associated With Metastatic Castrate-resistant Prostate Cancer.

Authors:  Paul R Sieber
Journal:  Rev Urol       Date:  2014

3.  Abiraterone in metastatic prostate cancer without previous chemotherapy.

Authors:  Charles J Ryan; Matthew R Smith; Johann S de Bono; Arturo Molina; Christopher J Logothetis; Paul de Souza; Karim Fizazi; Paul Mainwaring; Josep M Piulats; Siobhan Ng; Joan Carles; Peter F A Mulders; Ethan Basch; Eric J Small; Fred Saad; Dirk Schrijvers; Hendrik Van Poppel; Som D Mukherjee; Henrik Suttmann; Winald R Gerritsen; Thomas W Flaig; Daniel J George; Evan Y Yu; Eleni Efstathiou; Allan Pantuck; Eric Winquist; Celestia S Higano; Mary-Ellen Taplin; Youn Park; Thian Kheoh; Thomas Griffin; Howard I Scher; Dana E Rathkopf
Journal:  N Engl J Med       Date:  2012-12-10       Impact factor: 91.245

4.  Population-based impact on overall survival after the introduction of docetaxel as standard therapy for metastatic castration resistant prostate cancer.

Authors:  Robert R Zielinski; Arun A Azad; Kim N Chi; Scott Tyldesely
Journal:  Can Urol Assoc J       Date:  2014-07       Impact factor: 1.862

5.  Enzalutamide in metastatic prostate cancer before chemotherapy.

Authors:  Tomasz M Beer; Andrew J Armstrong; Dana E Rathkopf; Yohann Loriot; Cora N Sternberg; Celestia S Higano; Peter Iversen; Suman Bhattacharya; Joan Carles; Simon Chowdhury; Ian D Davis; Johann S de Bono; Christopher P Evans; Karim Fizazi; Anthony M Joshua; Choung-Soo Kim; Go Kimura; Paul Mainwaring; Harry Mansbach; Kurt Miller; Sarah B Noonberg; Frank Perabo; De Phung; Fred Saad; Howard I Scher; Mary-Ellen Taplin; Peter M Venner; Bertrand Tombal
Journal:  N Engl J Med       Date:  2014-06-01       Impact factor: 91.245

6.  Treatment evolution for metastatic castration-resistant prostate cancer with recent introduction of novel agents: retrospective analysis of real-world data.

Authors:  Thomas W Flaig; Ravi C Potluri; Yvette Ng; Mary B Todd; Maneesha Mehra
Journal:  Cancer Med       Date:  2015-12-29       Impact factor: 4.452

7.  Specific Anti-Leukemic Activity of the Peptide Warnericin RK and Analogues and Visualization of Their Effect on Cancer Cells by Chemical Raman Imaging.

Authors:  Clémence Loiseau; Jacques Augenstreich; Adrienne Marchand; Etienne Harté; Martine Garcia; Julien Verdon; Marc Mesnil; Sophie Lecomte; Jean-Marc Berjeaud
Journal:  PLoS One       Date:  2016-09-06       Impact factor: 3.240

Review 8.  Abiraterone acetate and prednisone in chemotherapy-naïve prostate cancer patients: rationale, evidence and clinical utility.

Authors:  E David Crawford; Neal D Shore; Daniel P Petrylak; Celestia S Higano; Charles J Ryan
Journal:  Ther Adv Med Oncol       Date:  2017-03-22       Impact factor: 8.168

9.  Population-based study on use of chemotherapy in men with castration resistant prostate cancer.

Authors:  Ingela Franck Lissbrant; Hans Garmo; Anders Widmark; Pär Stattin
Journal:  Acta Oncol       Date:  2013-02-21       Impact factor: 4.089

10.  Impact of comorbidity on the outcome in men with advanced prostate cancer treated with docetaxel.

Authors:  Andrej Zist; Eitan Amir; Alberto F Ocana; Bostjan Seruga
Journal:  Radiol Oncol       Date:  2015-11-27       Impact factor: 2.991
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.